These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 30513000)

  • 1. Therapeutic targets and early stage clinical trials for pulmonary fibrosis.
    Sato S; Yanagihara T; Kolb MRJ
    Expert Opin Investig Drugs; 2019 Jan; 28(1):19-28. PubMed ID: 30513000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic targets in idiopathic pulmonary fibrosis.
    Kolb M; Bonella F; Wollin L
    Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the treatment of idiopathic pulmonary fibrosis.
    Sergew A; Brown KK
    Expert Opin Emerg Drugs; 2015; 20(4):537-52. PubMed ID: 26629731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials.
    MacIsaac S; Somboonviboon D; Scallan C; Kolb M
    Expert Opin Emerg Drugs; 2024 Jun; 29(2):177-186. PubMed ID: 38588523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Existing and emerging treatments for idiopathic pulmonary fibrosis.
    Kolilekas L; Papiris S; Bouros D
    Expert Rev Respir Med; 2019 Mar; 13(3):229-239. PubMed ID: 30632421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging therapeutic targets for idiopathic pulmonary fibrosis: preclinical progress and therapeutic implications.
    Yanagihara T; Scallan C; Ask K; Kolb MRJ
    Expert Opin Ther Targets; 2021 Nov; 25(11):939-948. PubMed ID: 34784834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of animal models in IPF research.
    Carrington R; Jordan S; Pitchford SC; Page CP
    Pulm Pharmacol Ther; 2018 Aug; 51():73-78. PubMed ID: 29981850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging therapeutic interventions for idiopathic pulmonary fibrosis.
    Chakraborty S; Chopra P; Ambi SV; Dastidar SG; Ray A
    Expert Opin Investig Drugs; 2014 Jul; 23(7):893-910. PubMed ID: 24766571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials.
    Sgalla G; Lerede M; Richeldi L
    Expert Opin Emerg Drugs; 2021 Jun; 26(2):93-101. PubMed ID: 33998354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploitation of Novel Molecular Targets to Treat Idiopathic Pulmonary Fibrosis: A Drug Discovery Perspective.
    Vaidya B; Patel R; Muth A; Gupta V
    Curr Med Chem; 2017; 24(22):2439-2458. PubMed ID: 28552057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation and immunity in IPF pathogenesis and treatment.
    Heukels P; Moor CC; von der Thüsen JH; Wijsenbeek MS; Kool M
    Respir Med; 2019 Feb; 147():79-91. PubMed ID: 30704705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidative/nitrosative stress, autophagy and apoptosis as therapeutic targets of melatonin in idiopathic pulmonary fibrosis.
    Hosseinzadeh A; Javad-Moosavi SA; Reiter RJ; Yarahmadi R; Ghaznavi H; Mehrzadi S
    Expert Opin Ther Targets; 2018 Dec; 22(12):1049-1061. PubMed ID: 30445883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New therapeutics based on emerging concepts in pulmonary fibrosis.
    Sontake V; Gajjala PR; Kasam RK; Madala SK
    Expert Opin Ther Targets; 2019 Jan; 23(1):69-81. PubMed ID: 30468628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational drugs for idiopathic pulmonary fibrosis.
    Varone F; Montemurro G; Macagno F; Calvello M; Conte E; Intini E; Iovene B; Leone PM; Mari PV; Richeldi L
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1019-1031. PubMed ID: 28777013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis.
    Aryal S; Nathan SD
    Expert Opin Emerg Drugs; 2018 Jun; 23(2):159-172. PubMed ID: 29718783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The earlier, the better: Impact of early diagnosis on clinical outcome in idiopathic pulmonary fibrosis.
    Aiello M; Bertorelli G; Bocchino M; Chetta A; Fiore-Donati A; Fois A; Marinari S; Oggionni T; Polla B; Rosi E; Stanziola A; Varone F; Sanduzzi A
    Pulm Pharmacol Ther; 2017 Jun; 44():7-15. PubMed ID: 28257817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pamrevlumab for the treatment of idiopathic pulmonary fibrosis.
    Sgalla G; Franciosa C; Simonetti J; Richeldi L
    Expert Opin Investig Drugs; 2020 Aug; 29(8):771-777. PubMed ID: 32447983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New treatment and markers of prognosis for idiopathic pulmonary fibrosis: lessons learned from translational research.
    Baroke E; Gauldie J; Kolb M
    Expert Rev Respir Med; 2013 Oct; 7(5):465-78. PubMed ID: 24138691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease.
    Mora AL; Rojas M; Pardo A; Selman M
    Nat Rev Drug Discov; 2017 Nov; 16(11):755-772. PubMed ID: 28983101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done?
    Inchingolo R; Condoluci C; Smargiassi A; Mastrobattista A; Boccabella C; Comes A; Golfi N; Richeldi L
    Expert Opin Pharmacother; 2017 Oct; 18(15):1583-1594. PubMed ID: 28933616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.